UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 109

Sortiert nach

Antiangiogenic agents: current limits in thoracic oncology

Bulletin du cancer, 2012-11, Vol.99 (11), p.1083

2012

Volltextzugriff (PDF)

Les antiangiogéniques : limites actuelles en oncologie thoracique

Bulletin du cancer, 2012-11, Vol.99 (11), p.1083-1091

2012

Volltextzugriff (PDF)

Association between lung cancer somatic mutations and occupational exposure in never-smokers

The European respiratory journal, 2017-10, Vol.50 (4), p.1700716-1700716

2017

Volltextzugriff (PDF)

Asymptomatic Pelvic Metastasis from Thymic Carcinoma: A Case Report

Case reports in oncology, 2014-07, Vol.7 (2), p.422-425

2014

Volltextzugriff (PDF)

Asymptomatic pelvic metastasis from thymic carcinoma: a case report

Case reports in oncology, 2014, Vol.7 (2), p.422-425

2014

Volltextzugriff (PDF)

Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET)

Annals of oncology, 2020, Vol.31

2020

Volltextzugriff (PDF)

Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

Clinical cancer research, 2015-04, Vol.21 (8), p.1896-1903

2015

Volltextzugriff (PDF)

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

The European respiratory journal, 2015-05, Vol.45 (5), p.1403-1414

2015

Volltextzugriff (PDF)

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)

Lung cancer (Amsterdam, Netherlands), 2019-10, Vol.136, p.109-114

2019

Volltextzugriff (PDF)

Brigatinib in pretreated patients with ALK-positive advanced NSCLC

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9045-9045

2019

Volltextzugriff (PDF)

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

The lancet oncology, 2020-09, Vol.21 (9), p.1224-1233

2020

Volltextzugriff (PDF)

Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMIC

Journal of thoracic oncology, 2021-12, Vol.16 (12), p.2144-2149

2021

Volltextzugriff (PDF)

Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study

BMC cancer, 2018-04, Vol.18 (1), p.372-372, Article 372

2018

Volltextzugriff (PDF)

Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors

Clinical cancer research, 2006-06, Vol.12 (12), p.3774-3781

2006

Volltextzugriff (PDF)

Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e20507-e20507

2016

Volltextzugriff (PDF)

EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9062-9062

2021

Volltextzugriff (PDF)

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report

Case reports in oncology, 2015, Vol.8 (1), p.164-168

2015

Volltextzugriff (PDF)

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report

Case reports in oncology, 2015-01, Vol.8 (1), p.164-168

2015

Volltextzugriff (PDF)

Erlotinib versus standard chemotherapy as fi rst-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

The lancet oncology, 2012-03, Vol.13 (3), p.239

2012

Volltextzugriff (PDF)

Erratum to “Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network” [Lung Cancer, 97 (July 2016), 99–104]

Lung cancer (Amsterdam, Netherlands), 2016-11, Vol.101, p.146-146

2016

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(105)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(51)
Science & Technology
(51)
Humans
(46)
Oncology
(41)
Female
(37)
Male
(36)
Aged
(32)
Middle Aged
(31)
Life Sciences
(30)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(23)
Lung Neoplasms - Drug Therapy
(23)
Adult
(20)
Carcinoma, Non-Small-Cell Lung - Pathology
(19)
Lung Cancer
(19)
Lung Neoplasms - Pathology
(18)
Respiratory System
(18)
Cancer
(17)
Aged, 80 And Over
(13)
Chemotherapy
(13)
Neoplasm Staging
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antiangiogenic agents: current limits in thoracic oncology

Les antiangiogéniques : limites actuelles en oncologie thoracique

Association between lung cancer somatic mutations and occupational exposure in never-smokers

Asymptomatic Pelvic Metastasis from Thymic Carcinoma: A Case Report

Asymptomatic pelvic metastasis from thymic carcinoma: a case report

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET)

Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)

Brigatinib in pretreated patients with ALK-positive advanced NSCLC

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMIC

Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study

Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors

Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761)

EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report

Erlotinib versus standard chemotherapy as fi rst-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Erratum to “Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network” [Lung Cancer, 97 (July 2016), 99–104]

Suchergebnisse filtern